{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T06:30:00Z","timestamp":1793773800033,"version":"4.6.1"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.cca.2023.117623","type":"journal-article","created":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T19:44:31Z","timestamp":1698954271000},"page":"117623","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["M-protein detection by mass spectrometry for minimal residual disease in multiple myeloma"],"prefix":"10.1016","volume":"552","author":[{"given":"Lihua","family":"Guan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0734-8144","authenticated-orcid":false,"given":"Ling","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.cca.2023.117623_b0005","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41408-021-00408-4","article-title":"Mass Spectrometry for the Evaluation of Monoclonal Proteins in Multiple Myeloma and Related Disorders: An International Myeloma Working Group Mass Spectrometry Committee Report","volume":"11","author":"Murray","year":"2021","journal-title":"Blood Cancer J."},{"issue":"5","key":"10.1016\/j.cca.2023.117623_b0010","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and Management of Multiple Myeloma: A Review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.cca.2023.117623_b0015","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International Uniform Response Criteria for Multiple Myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.cca.2023.117623_b0020","doi-asserted-by":"crossref","first-page":"5428","DOI":"10.1158\/1078-0432.CCR-16-0866","article-title":"New Developments in Diagnosis, Prognosis, and Assessment of Response in Multiple Myeloma","volume":"22","author":"Landgren","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cca.2023.117623_b0025","unstructured":"New criteria for response assessment: role of minimal residual disease in multiple myeloma - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/25838346\/ (accessed 2023-10-18)."},{"issue":"23","key":"10.1016\/j.cca.2023.117623_b0030","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal Residual Disease Negativity Using Deep Sequencing Is a Major Prognostic Factor in Multiple Myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.cca.2023.117623_b0035","doi-asserted-by":"crossref","first-page":"e0237155","DOI":"10.1371\/journal.pone.0237155","article-title":"The Clinical Significance of Stringent Complete Response in Multiple Myeloma Is Surpassed by Minimal Residual Disease Measurements","volume":"15","author":"Cedena","year":"2020","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.cca.2023.117623_b0040","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2008-05-159624","article-title":"Multiparameter Flow Cytometric Remission Is the Most Relevant Prognostic Factor for Multiple Myeloma Patients Who Undergo Autologous Stem Cell Transplantation","volume":"112","author":"Paiva","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cca.2023.117623_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2019.09.622","article-title":"Minimal Residual Disease Status as a Surrogate Endpoint for Progression-Free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-Analysis","volume":"20","author":"Avet-Loiseau","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"8","key":"10.1016\/j.cca.2023.117623_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group Consensus Criteria for Response and Minimal Residual Disease Assessment in Multiple Myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"issue":"5771","key":"10.1016\/j.cca.2023.117623_b0055","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1126\/science.1124619","article-title":"Mass Spectrometry and Protein Analysis","volume":"312","author":"Domon","year":"2006","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.cca.2023.117623_b0060","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1515\/cclm-2020-0581","article-title":"Automation and Validation of a MALDI-TOF MS (Mass-Fix) Replacement of Immunofixation Electrophoresis in the Clinical Lab","volume":"59","author":"Kohlhagen","year":"2020","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.cca.2023.117623_b0065","unstructured":"Bringing mass spectrometry into the care of patients with multiple myeloma - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/35471500\/ (accessed 2023-10-18)."},{"issue":"3","key":"10.1016\/j.cca.2023.117623_b0070","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/clinchem\/hvz041","article-title":"Mass Spectrometry for Identification, Monitoring, and Minimal Residual Disease Detection of M-Proteins","volume":"66","author":"Zajec","year":"2020","journal-title":"Clin. Chem."},{"issue":"6","key":"10.1016\/j.cca.2023.117623_b0075","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1515\/cclm-2015-0580","article-title":"Laboratory Testing Requirements for Diagnosis and Follow-up of Multiple Myeloma and Related Plasma Cell Dyscrasias","volume":"54","author":"Willrich","year":"2016","journal-title":"Clin. Chem. Lab. Med."},{"issue":"1","key":"10.1016\/j.cca.2023.117623_b0080","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1373\/jalm.2019.029009","article-title":"Incidence and Management of Therapeutic Monoclonal Antibody Interference in Monoclonal Gammopathy Monitoring","volume":"5","author":"Liu","year":"2020","journal-title":"J. Appl. Lab. Med."},{"issue":"12","key":"10.1016\/j.cca.2023.117623_b0085","doi-asserted-by":"crossref","first-page":"5283","DOI":"10.1021\/acs.jproteome.5b00711","article-title":"Subset of Kappa and Lambda Germline Sequences Result in Light Chains with a Higher Molecular Mass Phenotype","volume":"14","author":"Barnidge","year":"2015","journal-title":"J. Proteome Res."},{"issue":"10","key":"10.1016\/j.cca.2023.117623_b0090","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1373\/clinchem.2015.253740","article-title":"Comprehensive Assessment of M-Proteins Using Nanobody Enrichment Coupled to MALDI-TOF Mass Spectrometry","volume":"62","author":"Mills","year":"2016","journal-title":"Clin. Chem."},{"key":"10.1016\/j.cca.2023.117623_b0095","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ymeth.2015.04.020","article-title":"Detecting Monoclonal Immunoglobulins in Human Serum Using Mass Spectrometry","volume":"81","author":"Mills","year":"2015","journal-title":"Methods"},{"issue":"3","key":"10.1016\/j.cca.2023.117623_b0100","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1021\/pr400985k","article-title":"Using Mass Spectrometry to Monitor Monoclonal Immunoglobulins in Patients with a Monoclonal Gammopathy","volume":"13","author":"Barnidge","year":"2014","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.cca.2023.117623_b0105","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.cca.2021.01.021","article-title":"Using MALDI-TOF Mass Spectrometry in Peripheral Blood for the Follow up of Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab-Based Combination Therapy","volume":"516","author":"Eveillard","year":"2021","journal-title":"Clin. Chim. Acta"},{"issue":"5","key":"10.1016\/j.cca.2023.117623_b0110","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/bjh.16443","article-title":"Comparison of MALDI-TOF Mass Spectrometry Analysis of Peripheral Blood and Bone Marrow-Based Flow Cytometry for Tracking Measurable Residual Disease in Patients with Multiple Myeloma","volume":"189","author":"Eveillard","year":"2020","journal-title":"Br J. Haematol."},{"issue":"10","key":"10.1016\/j.cca.2023.117623_b0115","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1373\/clinchem.2015.253781","article-title":"Screening Method for M-Proteins in Serum Using Nanobody Enrichment Coupled to MALDI-TOF Mass Spectrometry","volume":"62","author":"Kohlhagen","year":"2016","journal-title":"Clin. Chem."},{"issue":"16","key":"10.1016\/j.cca.2023.117623_b0120","doi-asserted-by":"crossref","first-page":"8268","DOI":"10.1021\/acs.analchem.5b01263","article-title":"Quantitative Measurement of Immunoglobulins and Free Light Chains Using Mass Spectrometry","volume":"87","author":"VanDuijn","year":"2015","journal-title":"Anal. Chem."},{"issue":"6","key":"10.1016\/j.cca.2023.117623_b0125","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/clinchem\/hvab017","article-title":"Clonotypic Features of Rearranged Immunoglobulin Genes Yield Personalized Biomarkers for Minimal Residual Disease Monitoring in Multiple Myeloma","volume":"67","author":"Langerhorst","year":"2021","journal-title":"Clin. Chem."},{"key":"10.1016\/j.cca.2023.117623_b0130","unstructured":"Development of a Targeted Mass-Spectrometry Serum Assay To Quantify M-Protein in the Presence of Therapeutic Monoclonal Antibodies - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/29424538\/ (accessed 2023-10-18)."},{"issue":"12","key":"10.1016\/j.cca.2023.117623_b0135","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1093\/clinchem\/hvab187","article-title":"Multiple Myeloma Minimal Residual Disease Detection: Targeted Mass Spectrometry in Blood vs Next-Generation Sequencing in Bone Marrow","volume":"67","author":"Langerhorst","year":"2021","journal-title":"Clin. Chem."},{"issue":"1","key":"10.1016\/j.cca.2023.117623_b0140","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1373\/clinchem.2015.242651","article-title":"Clonotypic Light Chain Peptides Identified for Monitoring Minimal Residual Disease in Multiple Myeloma without Bone Marrow Aspiration","volume":"62","author":"Bergen","year":"2016","journal-title":"Clin. Chem."},{"issue":"6","key":"10.1016\/j.cca.2023.117623_b0145","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1182\/blood.2021011101","article-title":"Prognostic Value of Minimal Residual Disease Negativity in Myeloma: Combined Analysis of POLLUX, CASTOR, ALCYONE, and MAIA","volume":"139","author":"Cavo","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.cca.2023.117623_b0150","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.2020010439","article-title":"Sustained Minimal Residual Disease Negativity in Newly Diagnosed Multiple Myeloma and the Impact of Daratumumab in MAIA and ALCYONE","volume":"139","author":"San-Miguel","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.cca.2023.117623_b0155","unstructured":"High sensitivity blood-based M-protein detection in sCR patients with multiple myeloma - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/28841203\/ (accessed 2023-10-18)."},{"issue":"2","key":"10.1016\/j.cca.2023.117623_b0160","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/bjh.17195","article-title":"Implications of Detecting Serum Monoclonal Protein by MASS-Fix Following Stem Cell Transplantation in Multiple Myeloma","volume":"193","author":"Abeykoon","year":"2021","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.cca.2023.117623_b0165","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41408-023-00803-z","article-title":"Dynamic Monitoring of Myeloma Minimal Residual Disease with Targeted Mass Spectrometry","volume":"13","author":"Noori","year":"2023","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.cca.2023.117623_b0170","unstructured":"Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/26631114\/ (accessed 2023-10-18)."},{"key":"10.1016\/j.cca.2023.117623_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2019.112991","article-title":"Bioanalytical Methods for Therapeutic Monoclonal Antibodies and Antibody-Drug Conjugates: A Review of Recent Advances and Future Perspectives","volume":"179","author":"Todoroki","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"6","key":"10.1016\/j.cca.2023.117623_b0180","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1182\/blood-2018-05-848986","article-title":"A Universal Solution for Eliminating False Positives in Myeloma Due to Therapeutic Monoclonal Antibody Interference","volume":"132","author":"Mills","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.cca.2023.117623_b0185","unstructured":"LIU JIa-Hui, FAN Hui-Shou, YAN Wen-Qiang, XU Jing-Yu, LI Ling-NA, XU Yan, YI Shu-Hua, ZOU De-Hui, QIU Lu-Gui, AN Gang. The Clinical Significant of Oligoclonal Bands in Patients with Multiple Myeloma. Journal of Experimental Hematology. 2022, No. 05 vo 30, 1453\u20131463. https:\/\/doi.org\/10.19746\/j.cnki.issn1009-2137.2022.05.023."},{"issue":"7","key":"10.1016\/j.cca.2023.117623_b0190","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.3324\/haematol.2013.084350","article-title":"Natural History and Prognostic Impact of Oligoclonal Humoral Response in Patients with Multiple Myeloma after Autologous Stem Cell Transplantation: Long-Term Results from a Single Institution","volume":"98","author":"Tovar","year":"2013","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.cca.2023.117623_b0195","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-019-0263-z","article-title":"Detection and Prevalence of Monoclonal Gammopathy of Undetermined Significance: A Study Utilizing Mass Spectrometry-Based Monoclonal Immunoglobulin Rapid Accurate Mass Measurement","volume":"9","author":"Murray","year":"2019","journal-title":"Blood Cancer J."},{"issue":"4","key":"10.1016\/j.cca.2023.117623_b0200","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/bjh.18226","article-title":"The Potential Role of Mass Spectrometry for the Identification and Monitoring of Patients with Plasma Cell Disorders: Where Are We Now and Which Questions Remain Unanswered?","volume":"198","author":"Giles","year":"2022","journal-title":"Br. J. Haematol."},{"issue":"12","key":"10.1016\/j.cca.2023.117623_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group Updated Criteria for the Diagnosis of Multiple Myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cca.2023.117623_b0210","unstructured":"Non-secretory multiple myeloma: Diagnosis and management - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/34637200\/ (accessed 2023-10-18)."},{"issue":"6","key":"10.1016\/j.cca.2023.117623_b0215","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1182\/blood.2021013794","article-title":"Redefining Nonmeasurable Multiple Myeloma Using Mass Spectrometry","volume":"139","author":"Giles","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.cca.2023.117623_b0220","unstructured":"XIANG Xue, CHAI Ye, WANG Xi, Ma Cheng-cheng, WANG Yin, LI Yan-Qing. Clinical Significance of sFLC\/MP Level and Light Chain Escape in Patients With Multiple Relapse. Journal pf Experimental Hematology. 2021, No. 06 vo 29, 1837\u20131844. https:\/\/doi.org\/10.19746\/j.cnki.issn1009-2137.2021.06.025."},{"issue":"22","key":"10.1016\/j.cca.2023.117623_b0225","doi-asserted-by":"crossref","first-page":"3414","DOI":"10.1182\/blood-2013-12-542662","article-title":"Serum Free Immunoglobulin Light Chain Evaluation as a Marker of Impact from Intraclonal Heterogeneity on Myeloma Outcome","volume":"123","author":"Brioli","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.cca.2023.117623_b0230","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41408-021-00418-2","article-title":"Measurable Residual Disease Assessed by Mass Spectrometry in Peripheral Blood in Multiple Myeloma in a Phase II Trial of Carfilzomib, Lenalidomide, Dexamethasone and Autologous Stem Cell Transplantation","volume":"11","author":"Derman","year":"2021","journal-title":"Blood Cancer J."},{"issue":"6","key":"10.1016\/j.cca.2023.117623_b0235","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1007\/s12185-022-03364-2","article-title":"Bringing Mass Spectrometry into the Care of Patients with Multiple Myeloma","volume":"115","author":"Murray","year":"2022","journal-title":"Int. J. Hematol."},{"issue":"20","key":"10.1016\/j.cca.2023.117623_b0240","doi-asserted-by":"crossref","first-page":"6933","DOI":"10.1002\/cam4.4254","article-title":"Comparison of Mass Spectrometry and Flow Cytometry in Measuring Minimal Residual Disease in Multiple Myeloma","volume":"10","author":"Foureau","year":"2021","journal-title":"Cancer Med."},{"key":"10.1016\/j.cca.2023.117623_b0245","unstructured":"Implications of detecting serum monoclonal protein by MASS-fix following stem cell transplantation in multiple myeloma - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/33216966\/ (accessed 2023-10-18)."},{"issue":"2","key":"10.1016\/j.cca.2023.117623_b0250","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s11899-021-00633-5","article-title":"MRD Assessment in Multiple Myeloma: Progress and Challenges","volume":"16","author":"Bertamini","year":"2021","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.cca.2023.117623_b0255","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.786451","article-title":"Assessment of Molecular Residual Disease Using Circulating Tumor DNA to Identify Multiple Myeloma Patients at High Risk of Relapse","volume":"12","author":"Dhakal","year":"2022","journal-title":"Front. Oncol."},{"issue":"22","key":"10.1016\/j.cca.2023.117623_b0260","doi-asserted-by":"crossref","first-page":"13686","DOI":"10.3390\/ijms232213686","article-title":"Detection of Measurable Residual Disease Biomarkers in Extracellular Vesicles from Liquid Biopsies of Multiple Myeloma Patients-A Proof of Concept","volume":"23","author":"Bergantim","year":"2022","journal-title":"Int. J. Mol. Sci."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898123004254?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898123004254?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T20:05:29Z","timestamp":1762113929000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898123004254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":52,"alternative-id":["S0009898123004254"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2023.117623","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"M-protein detection by mass spectrometry for minimal residual disease in multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2023.117623","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"117623"}}